ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug duo shows promise for tough head and neck cancers
Disease control CompletedThis study tested a combination of two drugs, duvelisib and docetaxel, in 26 people with head and neck cancer that had come back or spread and could not be cured. The goal was to see if the combo could shrink tumors. The approach is for disease control, not a cure, as ongoing man…
Matched conditions: ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Glenn J. Hanna • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New combo therapy shows promise for tough head and neck cancers
Disease control CompletedThis study tested a treatment that combines a short, intense type of radiation (quad-shot) with immunotherapy drugs for people with advanced or recurrent head and neck cancer that cannot be cured. The goal was to see if this combination could shrink tumors and be tolerable. The s…
Matched conditions: ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New combo therapy targets Hard-to-Treat cancers
Disease control CompletedThis early-stage trial tested a new drug called CyPep-1, injected directly into tumors, combined with the immunotherapy pembrolizumab. It included 6 adults with advanced head and neck cancer, melanoma, or triple-negative breast cancer that had spread. The goal was to see if the c…
Matched conditions: ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Cytovation AS • Aim: Disease control
Last updated May 19, 2026 12:01 UTC